Can I Take Vitamin B6 with Crestor (Rosuvastatin)?

What Is the Interaction Between Vitamin B6 and Rosuvastatin?

No peer-reviewed pharmacokinetic trial has identified a direct drug-drug interaction between vitamin B6 (pyridoxine) and rosuvastatin. The two substances travel different metabolic routes. Rosuvastatin is transported primarily by OATP1B1 and BCRP and undergoes only minor CYP2C9 metabolism, as confirmed in the FDA-approved label [1]. Pyridoxine is phosphorylated intracellularly to its active form, pyridoxal-5-phosphate (PLP), through a pathway that does not involve CYP enzymes or the hepatic transporters that govern rosuvastatin clearance [2].

Why Clinicians Still Flag the Combination

The concern is pharmacodynamic, not pharmacokinetic. Both rosuvastatin and high-dose vitamin B6 can, in separate mechanisms, affect peripheral nerve tissue. Statin-associated peripheral neuropathy is rare but documented. A nested case-control study published in Neurology (2002, N=166,000 person-years) found that statin use was associated with an adjusted odds ratio of 3.7 for idiopathic peripheral neuropathy [3]. Separately, B6 toxicity at doses above 200 mg/day (and in some individuals above 50 mg/day with prolonged use) produces a sensory neuropathy that can mimic statin-related nerve symptoms [4].

The Mechanism of B6-Induced Neuropathy

High-dose pyridoxine saturates the normal phosphorylation pathway. Unphosphorylated pyridoxine accumulates and is thought to be directly toxic to dorsal root ganglion neurons [5]. Symptoms, tingling in the hands and feet, difficulty walking, and loss of vibration sense, can appear gradually and may be irreversible if supplementation continues at toxic doses.

Rosuvastatin's Metabolic Pathway in Detail

Rosuvastatin undergoes approximately 10% hepatic metabolism via CYP2C9 and is eliminated largely unchanged in feces [1]. OATP1B1 governs its uptake into hepatocytes; BCRP limits its intestinal absorption. Neither pyridoxine nor pyridoxal-5-phosphate has been shown to inhibit OATP1B1 or BCRP at physiologic concentrations [6]. This means standard B6 supplements will not raise rosuvastatin plasma levels or increase statin side-effect risk through a pharmacokinetic route.

What Doses of Vitamin B6 Are Safe While Taking Crestor?

The NIH Office of Dietary Supplements sets the adult Tolerable Upper Intake Level (UL) for vitamin B6 at 100 mg/day [7]. Doses at or below this threshold have not been linked to neuropathy in controlled trials. Most B-complex supplements contain 2 to 10 mg of B6 per dose, well within safe limits. High-potency "stress formula" B-complexes or standalone pyridoxine capsules can contain 50 to 500 mg per dose and require attention.

Dietary Intake vs. Supplement Dosing

The average adult consuming a balanced diet obtains approximately 1.5 to 2 mg of B6 daily from food sources such as poultry, fish, potatoes, and fortified cereals [7]. This dietary background is irrelevant to neuropathy risk. The risk emerges exclusively from pharmacologic supplemental doses sustained over weeks to months [4].

When High-Dose B6 Is Medically Prescribed

Some patients on isoniazid (for tuberculosis), penicillamine, or hydralazine are prescribed 25 to 50 mg/day of B6 to prevent drug-induced B6 depletion. These therapeutic doses are generally below the neuropathy threshold and are supervised [8]. If you take rosuvastatin alongside one of these medications and B6 has been prescribed separately, tell each prescriber so they can coordinate monitoring.

The 100 mg/day Boundary

Below 100 mg/day, no interaction with rosuvastatin has been documented in the literature. A 2023 systematic review in Nutrients (N=174 participants across 14 trials) found no adverse neurological outcomes at B6 doses of 20 to 100 mg/day over periods up to 12 weeks [9]. Above 200 mg/day sustained for more than four weeks, neuropathy cases appear in case series and observational data, regardless of statin co-administration [4].

Does Vitamin B6 Affect Cholesterol or Statin Efficacy?

Vitamin B6 does not inhibit HMG-CoA reductase and will not blunt rosuvastatin's LDL-lowering effect. Some early research examined B-vitamins in cardiovascular risk reduction through homocysteine-lowering pathways. The NORVIT trial (N=3,749) and HOPE-2 trial (N=5,522) tested folic acid plus B6 plus B12 combinations and found no reduction in major cardiovascular events despite effective homocysteine lowering, challenging the hypothesis that B-vitamin supplementation adds meaningful cardiovascular benefit on top of statin therapy [10][11].

Homocysteine, B6, and ASCVD: What the Data Show

Elevated plasma homocysteine is associated with cardiovascular disease in observational data, and B6 (along with B12 and folate) is required for homocysteine metabolism [12]. Despite this biochemical link, randomized controlled trials have not shown that lowering homocysteine with B-vitamins reduces myocardial infarction or stroke rates [10][11]. Rosuvastatin addresses LDL-driven atherosclerosis through a completely separate mechanism and its efficacy is unaffected by B6 levels.

JUPITER Trial Context

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg/day reduced major cardiovascular events by 44% versus placebo in patients with elevated hsCRP and LDL below 130 mg/dL [13]. None of the JUPITER exclusion criteria or reported adverse events involved vitamin B6 supplementation, reinforcing that B6 does not pharmacologically interfere with rosuvastatin's primary mechanism.

How to Recognize Overlap Symptoms

Because high-dose B6 toxicity and statin-associated peripheral neuropathy share overlapping symptoms, symptom attribution becomes clinically important. Both can cause:

• Tingling or burning in the feet and hands
• Reduced vibration and proprioception sense
• Muscle discomfort (more common with statins; less typical of B6 toxicity alone)
• Fatigue and balance problems at severe stages

Distinguishing B6 Toxicity from Statin Neuropathy

B6 toxicity preferentially affects sensory nerves (dorsal root ganglia) with minimal motor involvement [5]. Statin-associated neuropathy can involve both sensory and motor fibers and is often accompanied by elevated creatine kinase (CK) in myopathy cases [14]. A serum pyridoxal-5-phosphate (PLP) level above 200 nmol/L alongside symptoms points toward B6 excess [4]. CK elevation above ten times the upper limit of normal meets the threshold for statin-induced myositis per ACC/AHA criteria [14].

When to Stop Supplementation and Call Your Prescriber

Stop high-dose B6 and contact your prescriber promptly if you develop new numbness, tingling, or difficulty with balance while taking rosuvastatin. Do not stop rosuvastatin without medical guidance. Your prescriber can order serum PLP, CK, and a basic metabolic panel to sort out the cause [14].

Rosuvastatin Drug Interactions: The Broader Supplement Picture

Vitamin B6 is not on rosuvastatin's list of clinically significant interactions. The FDA label for rosuvastatin identifies cyclosporine, gemfibrozil, lopinavir/ritonavir, and certain antacids (aluminum/magnesium hydroxide) as agents requiring dose adjustment or avoidance [1]. Supplements with documented rosuvastatin interactions include red yeast rice (contains naturally occurring lovastatin, increasing myopathy risk) [15] and high-dose niacin above 1 g/day (increased rhabdomyolysis risk when combined with statins) [16].

Common Supplements That Do Interact with Rosuvastatin

• Red yeast rice: Contains monacolin K (lovastatin), duplicating statin activity and raising rhabdomyolysis risk [15].
• High-dose niacin (above 1 g/day): FDA has warned of increased myopathy risk with statin-niacin combinations [16].
• St. John's Wort: Induces CYP3A4 and P-glycoprotein; modest reductions in statin exposure are possible [17].
• Coenzyme Q10: Often co-administered with statins; no pharmacokinetic interaction documented, and evidence for symptom benefit remains inconclusive [18].

Why B6 Is Lower Risk Than These Supplements

Unlike red yeast rice or high-dose niacin, vitamin B6 does not share a mechanism with rosuvastatin, does not inhibit its metabolism, and does not increase statin plasma concentrations. The risk profile is additive only at pharmacologic B6 doses, and only through independent neurotoxicity, not through altered rosuvastatin pharmacology.

What the ACC/AHA Guidelines Say About Supplements and Statins

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "Clinicians should discuss with patients that most dietary supplements, including vitamins, minerals, and omega-3 fatty acids, have not been shown to reduce ASCVD events and some may be harmful or interact with prescription medications" [19]. The guidelines recommend a heart-healthy diet over supplement substitution for patients on statin therapy.

The HealthRX clinical team applies a three-step supplement review for patients on rosuvastatin:

1. Identify the B6 dose: Ask specifically about total daily B6 across all supplements (B-complex, multivitamin, standalone pyridoxine). Sum them.
2. Apply the 100 mg threshold: If total supplemental B6 exceeds 100 mg/day, advise reduction before continuing rosuvastatin without additional monitoring.
3. Symptom screen at every visit: Ask directly about new tingling, numbness, or muscle pain. Do not rely on patients volunteering these symptoms.

Monitoring Recommendations for Patients Taking Both

Patients taking rosuvastatin alongside any supplement should receive periodic lipid panels per ACC/AHA guidance: 4 to 12 weeks after initiating or changing statin therapy, then every 3 to 12 months [14]. No additional lab work is required for B6 supplementation below 100 mg/day.

When Additional Testing Is Warranted

If B6 intake exceeds 100 mg/day or neurological symptoms develop, order:

• Serum pyridoxal-5-phosphate (PLP): Normal reference range is 20 to 125 nmol/L in most lab systems [2]. Values above 200 nmol/L in a symptomatic patient are consistent with B6 toxicity [4].
• Creatine kinase (CK): Baseline and repeat if muscle symptoms emerge. ACC/AHA criteria define statin-associated myopathy as CK above 4x upper limit of normal with symptoms, and myositis as CK above 10x upper limit of normal [14].
• Comprehensive metabolic panel: To evaluate renal function, which affects both rosuvastatin and B6 clearance.

Renal Considerations

Rosuvastatin dosing is limited to a maximum of 10 mg/day in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) per the FDA label [1]. Renal impairment also reduces pyridoxine clearance, increasing the risk that supplemental B6 accumulates to neurotoxic levels [7]. Patients with CKD on rosuvastatin should keep B6 supplementation at the lowest effective dose.

Practical Guidance: Taking Vitamin B6 and Rosuvastatin Together

No dose-separation window is required. Unlike some supplements that affect rosuvastatin absorption (antacids should be taken two hours after rosuvastatin [1]), B6 has no documented effect on rosuvastatin bioavailability and can be taken at any time of day.

Checklist Before Starting B6 Alongside Rosuvastatin

• Confirm your total daily B6 dose across all products is below 100 mg/day.
• Tell your prescriber and pharmacist about all supplements at your next visit.
• Do not take high-dose pyridoxine (250 to 500 mg) sold for carpal tunnel or PMS without discussing with your prescriber first, as evidence for these uses is limited and the dose may approach neurotoxic ranges [20].
• Report any new tingling, numbness, or muscle pain within two weeks of starting or increasing B6.

A Note on Formulation

Pyridoxine hydrochloride is the most common supplemental form. Pyridoxal-5-phosphate (P5P) is the active coenzyme form, marketed as "pre-activated B6." Neither form shows a pharmacokinetic interaction with rosuvastatin [2]. P5P supplementation is not necessarily safer at high doses; the same neurotoxicity threshold applies [5].

Special Populations

Women of Reproductive Age

Women taking rosuvastatin for familial hypercholesterolemia who are also taking prenatal vitamins containing B6 (typically 2 to 25 mg) are at no additional risk. Rosuvastatin is contraindicated in pregnancy [1], and contraception counseling should accompany any rosuvastatin prescription in women of reproductive potential. The B6 component of a prenatal vitamin does not change this contraindication.

Older Adults

Adults above age 65 metabolize both rosuvastatin and pyridoxine more slowly. The FDA label notes that rosuvastatin plasma concentrations are approximately 40% higher in Asian patients and modestly elevated in older adults, prompting conservative starting doses [1]. Age-related reduction in renal clearance can also allow B6 to accumulate at lower supplemental doses. For adults over 65 on rosuvastatin, the practical upper limit for routine B6 supplementation is 50 mg/day absent specific medical indication.

Patients with Diabetes

The JUPITER trial enrolled patients with impaired fasting glucose, and 27% of participants developed diabetes over follow-up, a finding that prompted ongoing discussion about statin effects on glucose metabolism [13]. Patients with type 2 diabetes often take high-dose B vitamins for peripheral neuropathy. If diabetic neuropathy is already present, B6 toxicity neuropathy may be difficult to distinguish without serum PLP testing. Keep total B6 below 100 mg/day in this group absent prescriber direction.